Company Filing History:
Years Active: 2008
Title: Innovations of Fang Liao in Antibody Development
Introduction
Fang Liao is an accomplished inventor based in New York, NY (US). She has made significant contributions to the field of biotechnology, particularly in the development of antibody antagonists. Her work focuses on enhancing therapeutic options while minimizing adverse effects.
Latest Patents
Fang Liao holds a patent for "Antibody antagonists of VE-cadherin without adverse effects on vascular permeability." This innovative patent highlights the murine epitope sequence recognized by antibody E4B9, which shares 100% homology with human VE-cadherin. The antibody was examined to determine its cross-reactivity with human VE-cadherin. Western-blot analysis confirmed that E4B9 indeed cross-reacts with human VE-cadherin, facilitating the development of a 'humanized' E4B9 antibody. This advancement is crucial for preclinical development, as it allows for extensive testing of its anti-tumor activity in various mouse models.
Career Highlights
Fang Liao is currently employed at Imclone Systems, Inc., where she continues to push the boundaries of antibody research. Her innovative approach and dedication to her work have positioned her as a key player in the biotechnology sector.
Collaborations
Fang has collaborated with notable colleagues, including Daniel J Hicklin and Peter Bohlen. These partnerships have further enriched her research and contributed to the success of her projects.
Conclusion
Fang Liao's contributions to antibody development exemplify her commitment to advancing medical science. Her innovative patent and collaborative efforts highlight her role as a leading inventor in the biotechnology field.